The $270M cash dividend creates a near-term floor for FULC shares. Traders should monitor the spread between current price and the implied value of the cash dividend plus the stub equity. Key catalysts: Fulcrum stockholder vote, HSR clearance, and S-4 effectiveness. The stub value of the ~5% stake in Slate's pipeline (lead candidate SLTE-1009) is highly speculative and will determine long-term upside.
Price Chart
Executive Summary
Fulcrum Therapeutics (FULC) and Slate Medicines announced a definitive merger agreement in which Fulcrum will acquire Slate in an all-stock reverse merger. Fulcrum is valued at $31.3M and Slate at $350M, with a concurrent $245M PIPE led by Frazier Life Sciences. Pre-merger FULC stockholders will receive a special cash dividend of approximately $270M (subject to adjustment) and will own ~5% of the combined company, which will be renamed Slate Medicines and trade under the ticker SLTE. The deal is expected to close in Q4 2026.
Key Financial Metrics
Key Facts
- Fulcrum valued at $31.3M, Slate at $350M in all-stock merger
- $245M concurrent PIPE from Frazier Life Sciences, Forbion, RA Capital, and others
- Pre-merger FULC stockholders to own ~5% of combined company on a fully-diluted basis
- FULC stockholders to receive ~$270M special cash dividend (subject to adjustment based on net cash)
- Combined company to be renamed Slate Medicines, Inc. and trade under ticker SLTE
- Slate's management team to operate the combined company; Slate's board to control
- Expected closing in Q4 2026; subject to stockholder approvals, HSR clearance, and Nasdaq listing
- Slate's lead product candidate SLTE-1009 mentioned in forward-looking statements
Financial Impact
FULC stockholders to receive ~$270M cash dividend (~95% of current $285M market cap) plus a ~5% equity stake in the combined company; Slate valued at $350M with $245M PIPE providing cash runway into 2029
Risk Factors
- Deal may fail to close (requires Fulcrum stockholder approval, HSR clearance, Nasdaq listing)
- Cash dividend amount subject to downward adjustment based on Fulcrum's net cash at closing
- The 5% stub stake in the combined company has uncertain value given Slate's early-stage pipeline
- Termination fee of $10M payable by Fulcrum to Slate under certain circumstances
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-353280 |
| Document: 0001193125-26-353280-index-headers.html | 0001193125-26-353280 |
| Document: 0001193125-26-353280-index.html | 0001193125-26-353280 |
| Document: 0001193125-26-353280.txt | 0001193125-26-353280 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | S-4 | $3.85 $3.70 | ▲ +3.90% | ▲ +3.57% | $3.67 (+4.68%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▲ +1.56% | ▼ −0.42% | $3.67 (+4.43%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | 8-K | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | Press Release | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 10, 2026 7w ago | 8-K | $3.75 $3.82 | ▲ +1.87% | ▲ +2.78% | $3.67 (−2.13%) |
Jul 15, 2026 11w ago | 3 | $3.50 $3.71 | ▲ +6.00% | ▲ +2.38% | $3.67 (+4.86%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.55 $3.59 | ▲ +1.13% | ▼ −0.76% | $3.67 (+3.38%) |
Apr 27, 2026 22w ago | 8-K | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
Apr 27, 2026 22w ago | Press Release | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access